C

Caliway Biopharmaceuticals Co Ltd
TWSE:6919

Watchlist Manager
Caliway Biopharmaceuticals Co Ltd
TWSE:6919
Watchlist
Price: 153.5 TWD Market Closed
Market Cap: 238.1B TWD

Caliway Biopharmaceuticals Co Ltd's latest stock split occurred on Jul 14, 2025

The company executed a 10-for-1 stock split, meaning that for every share held, investors received 10 new shares.

Before the split, Caliway Biopharmaceuticals Co Ltd traded at 121.5 per share. Afterward, the share price was about 121.5.

The adjusted shares began trading on Jul 14, 2025. This was the only stock split in Caliway Biopharmaceuticals Co Ltd's history.

Last Splits:
Jul 14, 2025
10-for-1
Pre-Split Price
121.5 121.5
Post-Split Price
121.5
Before
After
Last Splits:
Jul 14, 2025
10-for-1

Caliway Biopharmaceuticals Co Ltd
Stock Splits History

Caliway Biopharmaceuticals Co Ltd Stock Splits Timeline
Jul 14, 2025
Jul 14, 2025
Split 10-for-1
x10
Pre-Split Price
121.5 121.5
Post-Split Price
121.5
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Jan 20, 2026
Linius Technologies Ltd
OTC:LNNTF
1-for-100
/100
0.0001 0.0001 USD N/A
Jan 20, 2026
Lotus Resources Ltd
OTC:LTSRF
1-for-11
/11
0.14 0.14 USD N/A
Jan 15, 2026
Amcor PLC
NYSE:AMCR
1-for-5
/5
8.46 8.46 USD N/A
Jan 8, 2026
Sumitomo Realty & Development Co Ltd
OTC:SURYY
2-for-1
x2
25.635 25.635 USD N/A
Dec 30, 2025
Adicet Bio Inc
NASDAQ:ACET
1-for-16
/16
0.4921 7.8736 USD 7.93 7.93 USD
Load More

Caliway Biopharmaceuticals Co Ltd
Glance View

Market Cap
238.1B TWD
Industry
Pharmaceuticals

Caliway Biopharmaceuticals Co. Ltd. offers pharmaceutical services. The company is headquartered in Taipei, New Taipei. The company went IPO on 2022-12-26. The drugs developed by the Company are all small molecule drugs, including CBL-514, CBA-539, CBO-012 and CBF-520. CBL-514 is used for non-surgical local fat reduction, cellulite, Baergen's disease and lipoma and others. The company is in the second clinical stage. CBA-539 is used for pigmentation, whitening and anti-aging, and it is in the non-clinical research stage. CBO-012 is in the non-clinical research stage for degenerative arthritis. CBF-520 is used for central obesity and non-alcoholic fatty liver disease, and it is in the non-clinical research stage. The firm's sales revenue comes from health food, which is sold by agents and distributors, with Taiwan and China as the main sales areas.

Intrinsic Value
163.05 TWD
Undervaluation 6%
Intrinsic Value
Price
C
Back to Top